ALMKT:EPA
Mauna Kea Technologies SA
€0.096
arrow_downward
-0.62%(-0.00060) 1D
Oct 30, 12:28:25 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Open
€0.10
High
€0.10
Low
€0.10
Mkt. cap
18.09M
Avg. vol.
472.04K
Volume
116.99K
P/E ratio
0.82
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
Open
€0.10
High
€0.10
Low
€0.10
Mkt. cap
18.09M
Avg. vol.
472.04K
Volume
116.99K
P/E ratio
0.82
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
News stories
From web sources and news partners
marketscreener.com
·
52 minutes ago
Cash burnout
Yahoo Finance
·
41 minutes ago
Invesco S&P 500 Equal Weight (RSP) Adds Moderna and PTC on Oct. 28
TradingView
·
2 hours ago
Stock Market Today: Dow Jones, S&P 500 Futures Trade Mixed as AMZN, INTC Slide After Q3 Earnings—DELL, LLY, AZN in Focus
Investing.com
·
4 hours ago
The S&P 500 Is Being Held Together With Glue, and the Cracks Are Showing
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA